What You Should Know:
– Mayo Clinic has announced the launch of Mayo Clinic Platform_Orchestrate, a new program designed to accelerate clinical development and help biopharma and medical device companies bring innovative therapies to patients faster.
– The program achieves this by providing collaborators with a single point of access to Mayo Clinic’s world-class research and clinical expertise, de-identified clinical data, and advanced artificial intelligence (AI) tools.
A Single Front Door for Innovation
Mayo Clinic Platform_Orchestrate acts as the front door for collaboration within the Mayo Clinic Platform’s ecosystem of clinical data, AI, and clinician expertise. By removing traditional barriers that slow clinical development, the program enables companies to move efficiently from discovery to delivery.
The streamlined entry point allows companies to access and accelerate innovation across three key areas:
- Discovery: Provides access to real-world clinical data and biospecimens.
- Validation: Offers rigorous testing and refinement of AI models and digital solutions.
- Deployment: Provides scalable infrastructure to integrate innovations across Mayo Clinic and its international network.
Clinical Development Capabilities
Leading life sciences and technology firms are already using the Mayo Clinic Platform_Orchestrate program, indicating strong industry demand for its capabilities. Early projects are focused on critical areas, including:
- Developing multimodal AI models for early disease detection.
- Creating tools that precisely identify patients for targeted therapies.
- Accelerating and diversifying clinical trial recruitment.
- Deploying validated digital health solutions at scale across U.S. and international care settings.
“Mayo Clinic Platform_Orchestrate was created to help our life sciences and biopharma partners bring therapies to patients safely and faster,” says Maneesh Goyal, chief operating officer, Mayo Clinic Platform. “By combining trusted data, advanced AI and Mayo Clinic’s scientific expertise, we are reimagining what’s possible in clinical development.”
